CN103717582B - 用作抗菌剂的异*唑衍生物 - Google Patents

用作抗菌剂的异*唑衍生物 Download PDF

Info

Publication number
CN103717582B
CN103717582B CN201280016114.4A CN201280016114A CN103717582B CN 103717582 B CN103717582 B CN 103717582B CN 201280016114 A CN201280016114 A CN 201280016114A CN 103717582 B CN103717582 B CN 103717582B
Authority
CN
China
Prior art keywords
methyl
base
azoles
different
butyramide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280016114.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103717582A (zh
Inventor
J·A·阿布拉米特
M·F·布朗
J·M·陈
M·梅尔尼克
J·I·蒙哥马利
U·赖利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN103717582A publication Critical patent/CN103717582A/zh
Application granted granted Critical
Publication of CN103717582B publication Critical patent/CN103717582B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280016114.4A 2011-04-08 2012-03-23 用作抗菌剂的异*唑衍生物 Expired - Fee Related CN103717582B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473540P 2011-04-08 2011-04-08
US61/473,540 2011-04-08
PCT/IB2012/051406 WO2012137094A1 (en) 2011-04-08 2012-03-23 Isoxazole derivatives useful as antibacterial agents

Publications (2)

Publication Number Publication Date
CN103717582A CN103717582A (zh) 2014-04-09
CN103717582B true CN103717582B (zh) 2015-09-30

Family

ID=45999906

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280016114.4A Expired - Fee Related CN103717582B (zh) 2011-04-08 2012-03-23 用作抗菌剂的异*唑衍生物

Country Status (14)

Country Link
US (1) US8748466B2 (https=)
EP (1) EP2694488B1 (https=)
JP (1) JP2014510132A (https=)
KR (1) KR20130140868A (https=)
CN (1) CN103717582B (https=)
AU (1) AU2012238374B2 (https=)
CA (1) CA2830920C (https=)
DK (1) DK2694488T3 (https=)
ES (1) ES2526687T3 (https=)
IL (2) IL228799A (https=)
MX (1) MX2013011526A (https=)
SG (1) SG193367A1 (https=)
WO (1) WO2012137094A1 (https=)
ZA (1) ZA201306736B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032147A2 (en) 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
DK2512474T3 (en) 2009-12-16 2014-12-01 Pfizer N-linked hydroxamic acid derivatives which can be used as antibacterial agents
MA34963B1 (fr) 2011-03-07 2014-03-01 Pfizer Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
US9937156B2 (en) * 2013-10-16 2018-04-10 The Board Of Regents Of The University Of Texas System Modulation of MRTF-A activity in pathologic fibrosis and wound healing
AU2014368619B2 (en) 2013-12-19 2018-11-22 Idorsia Pharmaceuticals Ltd Antibacterial 1H-indazole and 1H-indole derivatives
AR099612A1 (es) * 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
EP3134401B1 (en) 2014-04-22 2018-06-13 Novartis AG Isoxazoline hydroxamic acid derivatives as lpxc inhibitors
ES2687040T3 (es) 2014-05-16 2018-10-23 Idorsia Pharmaceuticals Ltd Derivados antibacterianos de quinazolin–4(3H)–ona
SG11201703992YA (en) 2014-11-19 2017-06-29 Actelion Pharmaceuticals Ltd Antibacterial benzothiazole derivatives
HRP20192009T1 (hr) 2014-12-16 2020-02-07 Novartis Ag Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105848A1 (es) * 2015-08-31 2017-11-15 Actelion Pharmaceuticals Ltd Derivados heterocíclicos antibacterianos
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
US10590498B2 (en) * 2016-05-17 2020-03-17 Lawrence Livermore National Security, Llc Compounds for reactivation of acetylcholinesterase and related compositions methods and systems
SG11201810656WA (en) 2016-06-14 2018-12-28 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
DE102016113269A1 (de) 2016-07-19 2018-01-25 Osram Opto Semiconductors Gmbh Leuchtvorrichtung für ein mobiles endgerät
TWI604678B (zh) * 2016-09-07 2017-11-01 國立暨南國際大學 Radio transmission system
AU2017337946B2 (en) * 2016-09-28 2020-05-07 Dong-A St Co., Ltd. Tetrahydropyridine derivatives and their use as antibacterial agents
US11186548B2 (en) 2017-11-23 2021-11-30 Lawrence Livermore National Security, Llc Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them
TW202039478A (zh) * 2018-11-21 2020-11-01 日商大正製藥股份有限公司 新穎咪唑衍生物
CN111944719B (zh) * 2020-08-14 2022-04-29 暨南大学 一株二恶烷降解菌is20及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1437349A1 (en) * 2001-07-20 2004-07-14 Laboratorios S.A.L.V.A.T., S.A. Substituted isoxazoles and the use thereof as antibiotics
CN101016270A (zh) * 2006-12-30 2007-08-15 天津药物研究院 取代的哌嗪基苯基异噁唑啉衍生物及其用途
WO2007093904A1 (en) * 2006-02-14 2007-08-23 Pfizer Products Inc. Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
WO2010032147A2 (en) * 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769461A (en) 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US5110831A (en) 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
GB2349884A (en) 1998-02-07 2000-11-15 British Biotech Pharm Antibacterial agents
GB9925470D0 (en) 1999-10-27 1999-12-29 Smithkline Beecham Plc Novel compounds
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
CA2851462A1 (en) 2003-01-08 2004-07-29 University Of Washington Antibacterial agents
GB0302431D0 (en) 2003-01-30 2003-03-05 Glaxo Group Ltd Novel compounds
MX2007006961A (es) 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.
WO2006118155A1 (ja) 2005-04-27 2006-11-09 Ishihara Sangyo Kaisha, Ltd. ビフェニル誘導体又はその塩、並びにそれらを有効成分として含有する農園芸用殺菌剤
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
WO2007069020A2 (en) 2005-12-15 2007-06-21 Vicuron Pharmaceuticals Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2008045671A1 (en) 2006-10-06 2008-04-17 Janssen Pharmaceutica, N.V. Matrix metalloprotease inhibitors
US7879911B2 (en) 2007-02-01 2011-02-01 Johnson Alan T Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
WO2008105515A1 (ja) 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. 新規なヒドロキサム酸誘導体
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
EP2315746A1 (en) 2008-08-04 2011-05-04 Schering Corporation Urea derivatives as antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
DK2512474T3 (en) 2009-12-16 2014-12-01 Pfizer N-linked hydroxamic acid derivatives which can be used as antibacterial agents
MA34963B1 (fr) 2011-03-07 2014-03-01 Pfizer Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1437349A1 (en) * 2001-07-20 2004-07-14 Laboratorios S.A.L.V.A.T., S.A. Substituted isoxazoles and the use thereof as antibiotics
WO2007093904A1 (en) * 2006-02-14 2007-08-23 Pfizer Products Inc. Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
CN101016270A (zh) * 2006-12-30 2007-08-15 天津药物研究院 取代的哌嗪基苯基异噁唑啉衍生物及其用途
WO2010032147A2 (en) * 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
3-(吗啉吡啶基)-5-取代异噁唑类化合物的合成及抗菌活性研究;杜光剑，等;《有机化学》;20091231;第29卷(第10期);第1575-1581页 *
Hydroxamic Acid Derivatives as Potent Peptide Deformylase Inhibitors and Antibacterial Agents;Christian Apfel，等;《J.Med.Chem.》;20000520;第43卷(第12期);第2324-2331页 *
Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections;Matthew F.Brown，等;《Journal of Medicinal Chemistry》;20111218;第55卷(第18期);第914-923页 *

Also Published As

Publication number Publication date
US20140024690A1 (en) 2014-01-23
DK2694488T3 (en) 2014-12-15
KR20130140868A (ko) 2013-12-24
MX2013011526A (es) 2013-12-06
EP2694488B1 (en) 2014-11-12
CN103717582A (zh) 2014-04-09
EP2694488A1 (en) 2014-02-12
ES2526687T3 (es) 2015-01-14
WO2012137094A1 (en) 2012-10-11
SG193367A1 (en) 2013-10-30
AU2012238374A1 (en) 2013-09-26
IL240078A0 (en) 2015-08-31
CA2830920C (en) 2015-07-14
IL228799A0 (en) 2013-12-31
JP2014510132A (ja) 2014-04-24
IL228799A (en) 2015-08-31
CA2830920A1 (en) 2012-10-11
ZA201306736B (en) 2014-11-26
US8748466B2 (en) 2014-06-10
AU2012238374B2 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
CN103717582B (zh) 用作抗菌剂的异*唑衍生物
TW200456B (https=)
US5716967A (en) Isoxazoline compounds as antiinflammatory agents
US8809333B2 (en) Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
CA2744756C (en) Monocarbams and their use as antibacterial agent
JP2005534618A (ja) 神経変性疾患用の、ｃ−ｊｕｎｎ−末端キナーゼ阻害剤としての７−アザインドール
JP2022500470A (ja) Ｌｐａアンタゴニストとしてのシクロペンチル酸
US9855267B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
JPWO2008105515A1 (ja) 新規なヒドロキサム酸誘導体
JP7012289B2 (ja) ベンゾイルグリシン誘導体およびその作製および使用の方法
TW202023561A (zh) 抗菌化合物
JP2022500473A (ja) Ｌｐａアンタゴニストとしてのオキサビシクロ酸
CN103974953A (zh) 激酶抑制剂
TW200946117A (en) Compounds having NPY Y5 receptor antagonistic activity
US20170119795A1 (en) Fused triterpene compounds and uses thereof
JP2025540714A (ja) Ｌｐａ受容体活性と関連する状態を処置するための化合物および組成物
HK1194368A (en) Isoxazole derivatives useful as antibacterial agents
AU2015203690A1 (en) Isoxazole derivatives useful as antibacterial agents
JP2020531496A (ja) 抗菌剤として有用な代謝的に安定したｎ−アシルアミノオキサジアゾール
HK40104425A (en) Benzoylglycine derivatives and methods of making and using same
HK1190155A (en) Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
WO2001066542A1 (en) Pyridonecarboxylic acid derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1194368

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150930

Termination date: 20160323

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1194368

Country of ref document: HK